论文部分内容阅读
目的探讨还原型谷胱甘肽治疗抗结核药物引起肝损害的临床效果。方法入选患者38例,全部确诊为结核性胸膜炎且在抗结核联合化疗中出现不同程度的肝损害,随机分为治疗组20例和对照组18例,治疗组口服还原型谷胱甘肽片(阿拓莫兰片),对照组口服肌苷、肝太乐等护肝药物,两组均采用相同基础治疗。结果治疗组ALT、AST、TB下降变化及前后变化优于对照组(P<0.01,P<0.05)。结论还原型谷胱甘肽对抗结核药物所致的肝损害有明显临床疗效。
Objective To investigate the clinical effect of reduced glutathione on liver damage induced by antituberculosis drugs. Methods Thirty-eight patients were enrolled and all were diagnosed as tuberculous pleurisy with varying degrees of liver damage during anti-TB combination chemotherapy. They were randomly divided into treatment group (20 cases) and control group (18 cases). The treatment group received oral reduced glutathione tablets A Tuolan Lan tablets), the control group oral inosine, liver too much liver drug, both groups were treated with the same basis. Results The changes of ALT, AST and TB in the treatment group were better than those in the control group (P <0.01, P <0.05). Conclusion Reduced glutathione has obvious curative effect on liver damage caused by antituberculosis drugs.